ITGB1 and metabolic dysfunction-associated steatohepatitis: Hence, these authors propose that reducing the ability of LSECs to recruit harmful proinflammatory monocytes through ITGβ1 inhibition may serve as an anti-inflammatory therapeutic strategy to combat NASH.